Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.
Celgene Reports Positive Data on Dermatology Drug Otezla
by Zacks Equity Research
Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
This biotech ETF hit a new 52-week high. Are more gains in store for this fund?
Company News For Jan 26, 2018
by Zacks Equity Research
Companies in the news are: CELG,FCX,EGHT,ALK
Infinity Provides Update on Lead Candidate, Issues 2018 View
by Zacks Equity Research
Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.
Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?
by Zacks Equity Research
J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.
Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid
by Zacks Equity Research
Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.
Celgene (CELG) Beats on Q4 Earnings
by Ekta Bagri
Celgene topped earnings expectations in the fourth quarter of 2017. The company also surpassed sales estimates.
Play Biotech Buyout Frenzy With These 2 Solid Funds
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas
Stock Market News For Jan 23, 2018
by Zacks Equity Research
Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown.
Bluebird Up on Buyout Speculation After Celgene/Juno Deal
by Zacks Equity Research
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion
by Zacks Equity Research
Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.
Biotech ETF (BBC) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?
by Arpita Dutt
Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?
Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?
by Zacks Equity Research
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year
by Zacks Equity Research
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?
by Zacks Equity Research
J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest
by Zacks Equity Research
Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.